
A retrospective study conducted in China from 2010 to 2020 revealed that intravenous immunoglobulin (IVIG) therapy may not effectively treat severe fever with thrombocytopenia syndrome (SFTS). The research, based on 2219 confirmed SFTS cases, showed a significantly higher case fatality rate (CFR) in the IVIG group (19%) compared to the non-IVIG group (4.6%). Even after propensity score matching, the CFR difference remained significant (17.2% vs. 5.1%). IVIG therapy was associated with higher viral loads and decreased blood cell counts. The findings suggest caution in prescribing IVIG for SFTS patients and question its efficacy in improving outcomes.
Like
Save
Share